Clinical Trials
4
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Phase 2
Recruiting
- Conditions
- Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT06951217
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Australia
🇦🇺The Prince Charles Hospital (TPCH), Chermside, Australia
🇦🇺Respiratory Clinical Trials PTY Ltd, Kent Town, Australia
A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis
Phase 2
Recruiting
- Conditions
- Progressive Pulmonary Fibrosis
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 141
- Registration Number
- 2023-508429-29-00
- Locations
- 🇩🇪
Muenchen Klinik gGmbH, Munich, Germany
🇩🇪Universitaet Leipzig, Leipzig, Germany
🇩🇪Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH, Essen, Germany
News
Avalyn Pharma Unveils AURA-IPF Phase 2 Trial Design for Inhaled Nintedanib at ERS Congress 2025
Avalyn Pharma will present the AURA-IPF Phase 2 clinical trial design for AP02, an inhaled formulation of nintedanib, at the European Respiratory Society International Congress 2025.